Actively Recruiting
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Led by Shandong Public Health Clinical Center · Updated on 2025-07-17
30
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase II, single-arm study to evaluate the efficacy and safety of Afatinib plus chemotherapy as conversion treatment in patients with unresectable EGFR sensitive mutation-positive stage III non-small cell lung cancer.
CONDITIONS
Official Title
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically or cytologically confirmed unresectable Stage III non-small cell lung cancer
- Positive test for EGFR sensitive mutation in tissue or blood samples
- ECOG Performance Status of 0 or 1
- At least one measurable tumor lesion according to RECIST 1.1
- Adequate organ and marrow function
You will not qualify if you...
- Combined small cell lung cancer and non-small cell lung cancer, large cell neuroendocrine carcinoma, or sarcoma-like carcinoma
- Presence of malignant pleural effusion
- Prior systemic anti-cancer treatment for non-small cell lung cancer
- Prior local radiotherapy for non-small cell lung cancer
- Uncontrolled gastrointestinal diseases affecting drug absorption such as Crohn's disease, ulcerative colitis, absorption disorders, or diarrhea of Grade 2 or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong Public Health Clinical Center
Jinan, Shangdong, China, 250000
Actively Recruiting
Research Team
H
Hua Zhang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here